Corpeleijn, Willemijn E.
de Waal, Wouter J.
Schipper, Henk S.
Wiegman, Albert
Article History
Received: 3 March 2023
Accepted: 14 August 2023
First Online: 30 November 2023
Authors’ relationships and activities
: AW reports research support for pharmaceutical trials of lipid modification agents from Amgen, Regeneron, Novartis, Silence Therapeutics, Ultragenyx and Esperion and is a member of the safety board at Amryt. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: All authors contributed substantially to the conception and design of the work and drafting of the article (WEC) or reviewing it critically for important intellectual content (WJdW, HSS, AW). All authors approved the final version to be published.